Skip to main content

Advertisement

SpringerLink
Log in

Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The standardization of surgical outcomes throughout surgical procedures is mandatory. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) should provide proficient oncological and surgical outcomes.

Study Design

The aim of this study was to identify clinically relevant quality indicators and their quality standard, and to determine their acceptable quality limit. A systematic review on cytoreductive results from 2000 to 2018 was performed focusing on clinical guidelines, consensus conferences, and publications. After the selection of quality indicators, a systematic review of indexed references was performed in order to calculate the quality standard for each indicator.

Study Selection

Unicentric/multicentric series, comparative studies, and clinical trials. Studies were to include outcomes after cytoreduction of colorectal origin and series with more than 50 patients. Quality indicators with at least 10 series were mandatory and objective measurements were also mandatory for inclusion.

Main Outcome Measurements

Quality indicators selected were 1- to 5-year survival, overall disease-free survival, 1- to 5-year disease-free survival, complete surgical resection, duration of surgery, length of stay, overall morbimortality, major morbidity, re-intervention, postoperative hemorrhage, intestinal fistula, anastomotic leakage, wound infection, postoperative medical complications, overall recurrence, and failure to rescue.

Results

The most relevant quality indicators and critical quality limits were overall disease-free survival and 5-year overall disease-free survival (14 months and <10 months, and 14% and <4%, respectively), completeness of surgical resection (89% and <80%, respectively), overall mortality (3% and >8%, respectively), overall morbidity (47% and >63%, respectively), failure to rescue (12% and <30%, respectively), reintervention (13 and <22%, respectively), anastomotic leakage (6% and <13%, respectively), and overall recurrence (60% and <74%, respectively).

Conclusion

This is the first study to assess quality standards in CRS + HIPEC for colorectal peritoneal metastases. The current data are of particular relevance for future studies to control the variability of this surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Donabedian A. Evaluating the quality of medical care approaches to assessment: what to assess. Milbank Q. 2005;83(4):691–729.

    PubMed  PubMed Central  Google Scholar 

  2. Shewhart WA. Economic control of quality of manufactured product. 1931. Reprinted by ASQC Quality Press; 1980.

  3. Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med. 2005;24(8):1185–202.

    PubMed  Google Scholar 

  4. Noyez L. Control charts, Cusum techniques and funnel plots. A review of methods for monitoring performance in healthcare. Interact Cardiovasc Thorac Surg. 2009;9(3):494–9.

    PubMed  Google Scholar 

  5. Neuburger J, Walker K, Sherlaw-Johnson C, Van Der Meulen J, Cromwell DA. Comparison of control charts for monitoring clinical performance using binary data. BMJ Qual Saf. 2017;26(11):919–28.

    PubMed  PubMed Central  Google Scholar 

  6. Courrech Staal EFW, Wouters MWJM, Boot H, Tollenaar RAEM, Van Sandick JW. Quality-of-care indicators for oesophageal cancer surgery: A review. Eur J Surg Oncol. 2010;36:1035–43.

    CAS  PubMed  Google Scholar 

  7. Dikken JL, Stiekema J, Van De Velde CJH, Verheij M, Cats A, Wouters MWJM, et al. Quality of care indicators for the surgical treatment of gastric cancer: a systematic review. Ann Surg Oncol. 2013;20:381–98.

    PubMed  Google Scholar 

  8. Sabater L, García-Granero A, Escrig-Sos J, del Gómez-Mateo MC, Sastre J, Ferrández A, et al. Outcome quality standards in pancreatic oncologic surgery. Ann Surg Oncol. 2014;21:1138–46.

    PubMed  Google Scholar 

  9. Stordeur S, Vrijens F, Devriese S, Beirens K, Van Eycken E, Vlayen J. Developing and measuring a set of process and outcome indicators for breast cancer. Breast. 2012;21(3):253–60.

    PubMed  Google Scholar 

  10. Vlayen J, Vrijens F, Devriese S, Beirens K, Van Eycken E, Stordeur S. Quality indicators for testicular cancer: a population-based study. Eur J Cancer. 2012;48(8):1133–40.

    PubMed  Google Scholar 

  11. National Institute for Health and Care Excellence (NICE). Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. NICE; 2010.

  12. Barrios P, Ramos I, Escayola C MM. Implementación y desarrollo de un programa de tratamiento de la carcinomatosis peritoneal en Cataluña. Indicaciones y resultados clínicos con la técnica de Sugarbaker. Barcelona: Catalan Agency for Health Information, Evaluation and Quality (CAHIAQ -formerly CAHTA). 2009

  13. National Institute for Health and Care Excellence (NICE). Colorectal cancer: diagnosis and management. NICE; 2011.

  14. Cancer IN Du. Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique. Cancer colorectal. Adénocarcinome. Haute Autorité de Santé; 2012.

  15. Peeters M, Leroy R, Robays J, Veereman G, Bielen D, Ceelen W, Danse E, De Man M, Demetter P, Flamen P, Hendlisz A, Sinapi I, Vanbeckevoort D, Van Cutsem E, Ysebaert D, van Gils P, Veerbeek L, Smit Y VL. Colon cancer: diagnosis, treatment and follow-up—summary. Good Clinical Practice (GCP) Brussels; 2014.

  16. Dubé P, Sideris L, Law C, Mack L, Haase E, Giacomantonio C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22(2):e100–12.

    PubMed  PubMed Central  Google Scholar 

  17. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.

    PubMed  Google Scholar 

  18. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS. SSO TOS Ann Oncol. 2018;29(1):44–70.

    CAS  PubMed  Google Scholar 

  19. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American society of colon and rectal surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum. 2017;60(10):999–1017.

    PubMed  Google Scholar 

  20. Morales Soriano R, Cascales Campos P GMJ. Cirugía de la carcinomatosis peritoneal. Asociación Española de Cirujanos. Arán Edici; 2018.

  21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 3.2020. NCCN; 2020.

  22. Phelip JM, Tougeron D, Léonard D, Benhaim L, Desolneux G, Dupré A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51:1357–63.

    PubMed  Google Scholar 

  23. Kusamura S, Baratti D, Younan R, Deraco M. The Delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol. 2008;98(4):217–9.

    PubMed  Google Scholar 

  24. Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263–7.

    PubMed  Google Scholar 

  25. Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, Moran BJ. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. Ann Surg Oncol. 2012;19:4244–51.

    PubMed  Google Scholar 

  26. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.

    CAS  PubMed  Google Scholar 

  27. Kuijpers AMJ, Mirck B, Aalbers AGJ, Nienhuijs SW, De Hingh IHJT, Wiezer MJ, et al. Cytoreduction and HIPEC in the Netherlands: Nationwide long-term outcome following the dutch protocol. Ann Surg Oncol. 2013;20(13):4224–30.

    PubMed  PubMed Central  Google Scholar 

  28. Van De Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1.e1-1.e34.

    Google Scholar 

  29. Esquivel J, Piso P, Verwaal V, Bachleitner-Hofmann T, Glehen O, González-Moreno S, et al. American Society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110:777–8.

    PubMed  Google Scholar 

  30. Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016;7:99–111.

    PubMed  PubMed Central  Google Scholar 

  31. Li Y, Zhou YF, Liang H, Wang HQ, Hao JH, Zhu ZG, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22:6906–16.

    PubMed  PubMed Central  Google Scholar 

  32. Klaver CEL, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19:224–36.

    CAS  PubMed  Google Scholar 

  33. Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114(2):222–7.

    PubMed  Google Scholar 

  34. Kwakman R, Schrama AM, Van Olmen JP, Otten RH, De Lange-De Klerk ES, De Cuba EM, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases a meta-analysis. Ann Surg. 2016;263(6):1102–11.

    PubMed  Google Scholar 

  35. Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.

    PubMed  Google Scholar 

  36. Quadros CA, Laporte GA, Huguenin JFL, Barreto EJSS, Barros AV, Oliveira AF, et al. Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol. 2018;44(11):1800–4.

    Google Scholar 

  37. Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942–8.

    CAS  PubMed  Google Scholar 

  38. Abboud K, André T, Brunel M, Ducreux M, Eveno C, Glehen O, et al. Management of colorectal peritoneal metastases: expert opinion. J Visc Surg. 2019;156(5):377–9.

    CAS  PubMed  Google Scholar 

  39. Brett CE. My systematic review don’t do it alone don’t be over - (or under-) ambitious pilot, pilot, and pilot. record everything you do. Long list to short list PRISMA flowchart. Short list to review. Phys Ther. 2014;89(9):1–5.

    Google Scholar 

  40. Blackham AU, Russell GB, Stewart JH, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21(8):2667–74.

    PubMed  PubMed Central  Google Scholar 

  41. Wong EYT, Tan GHC, Ng DWJ, Koh TPT, Kumar M, Teo MCC. Surgical management of metastatic colorectal cancer: a single-centre experience on oncological outcomes of pulmonary resection vs cytoreductive surgery and HIPEC. J Gastrointest Cancer. 2017;48(4):353–60.

    CAS  PubMed  Google Scholar 

  42. Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, et al. Peritoneal surface disease from colorectal cancer: Comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol. 2008;15(12):3422–32.

    PubMed  Google Scholar 

  43. Huang CQ, Feng JP, Yang XJ, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center. J Surg Oncol. 2014;109(7):730–9.

    PubMed  Google Scholar 

  44. Lorimier G, Linot B, Paillocher N, Dupoiron D, Verrièle V, Wernert R, et al. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 2017;43(1):150–8.

    CAS  PubMed  Google Scholar 

  45. Ng JL, Ong WS, Chia CS, Tan GHC, Soo KC, Teo MCC. Prognostic relevance of the peritoneal surface disease severity score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis. Int J Surg Oncol. 2016;2016:2495131.

    PubMed  PubMed Central  Google Scholar 

  46. Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Color Dis. 2015;17(9):772–8.

    CAS  Google Scholar 

  47. Simkens GA, Van Oudheusden TR, Braam HJ, Wiezer MJ, Nienhuijs SW, Rutten HJ, et al. Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study. J Surg Oncol. 2016;113(5):548–53.

    PubMed  Google Scholar 

  48. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.

    CAS  PubMed  Google Scholar 

  49. da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86.

    PubMed  Google Scholar 

  50. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(5):1330–6.

    PubMed  Google Scholar 

  51. Cavaliere F, De Simone M, Virz S, Deraco M, Rossi CR, Garofalo A, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37(2):148–54.

    CAS  PubMed  Google Scholar 

  52. Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18(13):3673–9.

    PubMed  PubMed Central  Google Scholar 

  53. Passot G, Vaudoyer D, Cotte E, You B, Isaac S, Noël Gilly F, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256(1):125–9.

    PubMed  Google Scholar 

  54. Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18(5):1024–31.

    PubMed  Google Scholar 

  55. Braam HJ, Van Oudheusden TR, De Hingh IHJT, Nienhuijs SW, Boerma D, Wiezer MJ, et al. Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: morbidity and survival analysis. Anticancer Res. 2015;35(1):295–300.

    PubMed  Google Scholar 

  56. Levine EA, Stewart JH IV, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573–85.

    PubMed  Google Scholar 

  57. Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–64.

    PubMed  Google Scholar 

  58. Dodson RM, McQuellon RP, Mogal HD, Duckworth KE, Russell GB, Votanopoulos KI, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772–83.

    PubMed  PubMed Central  Google Scholar 

  59. Navez J, Remue C, Leonard D, Bachmann R, Kartheuser A, Hubert C, et al. Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: report from a single-centre experience. Ann Surg Oncol. 2016;23(S5):666–73.

    PubMed  Google Scholar 

  60. Saxena A, Valle SJ, Liauw W, Morris DL. Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;115(4):417–24.

    PubMed  Google Scholar 

  61. Demey K, Wolthuis A, de Buck van Overstraeten A, Fieuws S, Vandecaveye V, Van Cutsem E, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017;24(12):3604–8.

    PubMed  Google Scholar 

  62. Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.

    PubMed  Google Scholar 

  63. Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23(1):114–9.

    PubMed  Google Scholar 

  64. Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzì S, et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57(7):858–68.

    CAS  PubMed  Google Scholar 

  65. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245(4):597–603.

    PubMed  PubMed Central  Google Scholar 

  66. Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol. 2012;38(6):509–15.

    CAS  PubMed  Google Scholar 

  67. Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Results of two Bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254(2):294–301.

    PubMed  Google Scholar 

  68. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(13):4195–201.

    PubMed  Google Scholar 

  69. Bong TSH, Tan GHC, Chia C, Soo KC, Teo MCC. Preoperative platelet–lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Clin Oncol. 2017;22(3):511–8.

    CAS  PubMed  Google Scholar 

  70. Kozman MA, Fisher OM, Rebolledo BAJ, Parikh R, Valle SJ, Arrowaili A, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725–36.

    CAS  PubMed  Google Scholar 

  71. Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61(9):1026–34.

    PubMed  Google Scholar 

  72. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116(24):5608–18.

    PubMed  Google Scholar 

  73. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013:1–7.

    Google Scholar 

  74. Wehler TC, Graf C, Möhler M, Herzog JR, Berger M, Gockel I, et al. Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol. 2013;139:1961–2. https://doi.org/10.1007/s00432-013-1483-4.

    Article  CAS  PubMed Central  Google Scholar 

  75. Königsrainer I, Horvath P, Struller F, Forkl V, Königsrainer A, Beckert S. Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer-derived peritoneal surface malignancies. Langenbeck’s Arch Surg. 2013;398(5):745–9.

    Google Scholar 

  76. Desantis M, Bernard JL, Casanova V, Cegarra-Escolano M, Benizri E, Rahili AM, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck’s Arch Surg. 2015;400(1):37–48.

    Google Scholar 

  77. Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014;40(11):1467–73.

    CAS  PubMed  Google Scholar 

  78. Alzahrani N, Ferguson JS, Valle SJ, Liauw W, Chua T, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St George Hospital, Australia. ANZ J Surg. 2016;86(11):937–41.

    PubMed  Google Scholar 

  79. Huang Y, Alzahrani NA, Alzahrani SE, Zhao J, Liauw W, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly. World J Surg Oncol. 2015;13(1):262.

    PubMed  PubMed Central  Google Scholar 

  80. Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, et al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016;23(3):863–9.

    PubMed  Google Scholar 

  81. Ihemelandu C, Sugarbaker PH. Management for peritoneal metastasis of colonic origin: role of cytoreductive surgery and perioperative intraperitoneal chemotherapy: a single institution’s experience during two decades. Ann Surg Oncol. 2017 ;24(4):898–905.

    PubMed  Google Scholar 

  82. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard A-C, Bakrin N, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016 ;113(7):796–803.

    PubMed  Google Scholar 

  83. Banaste N, Rousset P, Mercier F, Rieussec C, Valette PJ, Glehen O, et al. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis. Int J Hyperth. 2018 ;34(5):589–94.

    CAS  Google Scholar 

  84. Saxena A, Liauw W, Virk SA, Morris DL. Impact of concomitant urologic intervention on clinical outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Am J Clin Oncol Cancer Clin Trials. 2018;41(10):943–8.

    Google Scholar 

  85. Massalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213(2):377–87.

    PubMed  Google Scholar 

  86. Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coupé VMH, Verheul HMW, et al. Metachronous peritoneal metastases after adjuvant chemotherapy are associated with poor outcome after cytoreduction and HIPEC. Ann Surg Oncol. 2018;25(8):2347–56.

    PubMed  PubMed Central  Google Scholar 

  87. Tan G, Chia C, Kumar M, Choo SP, Chia J, Tham CK, et al. 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperth. 2017;33(3):288–94.

    CAS  Google Scholar 

  88. Lee L, Alie-Cusson F, Dubé P, Sideris L. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Surg Oncol. 2017;116(2):236–43.

    CAS  PubMed  Google Scholar 

  89. Devilee RA, Simkens GA, van Oudheusden TR, Rutten HJ, Creemers GJ, ten Tije AJ, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841–8.

    CAS  PubMed  Google Scholar 

  90. Cavaliere F, Valle M, DeSimone M, Deraco M, Rossi CR, DiFilippo F, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia. A S.I.T.I.L.O. multicentric study. in Vivo (Brooklyn). 2006;20(6):747–50.

    CAS  Google Scholar 

  91. Bijelic L, Yan TD, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2007;14(8):2281–8.

    PubMed  Google Scholar 

  92. Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg. 2010;34(1):70–8.

    PubMed  Google Scholar 

  93. Eveno C, Passot G, Goéré D, Soyer P, Gayat E, Glehen O, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21(6):1792–800.

    PubMed  Google Scholar 

  94. Votanopoulos KI, Swett K, Blackham AU, Ihemelandu C, Shen P, Stewart JH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. Ann Surg Oncol. 2013;20(4):1088–92.

    PubMed  PubMed Central  Google Scholar 

  95. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779–85.

    CAS  PubMed  Google Scholar 

  96. Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: Are we excluding patients who may benefit? J Surg Oncol. 2014;109(2):104–9.

    PubMed  Google Scholar 

  97. Van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, Van Ramshorst B, Luyer P, et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111(2):237–42.

    PubMed  Google Scholar 

  98. Cashin PH, Dranichnikov F, Mahteme H. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate. J Surg Oncol. 2014;110(2):203–6.

    PubMed  Google Scholar 

  99. Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608–14.

    PubMed  Google Scholar 

  100. Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ, et al. Predictors of severe morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2016;23(3):833–41.

    PubMed  Google Scholar 

  101. Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144–9.

    CAS  PubMed  Google Scholar 

  102. Downs-Canner S, Shuai Y, Ramalingam L, Pingpank JF, Holtzman MP, Zeh HJ, et al. Safety and efficacy of combined resection of colorectal peritoneal and liver metastases. J Surg Res. 2017;219:194–201.

    PubMed  PubMed Central  Google Scholar 

  103. Van Eden WJ, Kok NF, Jóźwiak K, Lahaye ML, Beets GL, Van Leerdam ME, et al. Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Dis Colon Rectum. 2017;60(5):477–87.

    PubMed  Google Scholar 

  104. Elekonawo FMK, Van Der Meeren MMD, Simkens GA, De Wilt JHW, De Hingh IH, Bremers AJA. Comparison of 2 perioperative management protocols and their influence on postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: standard parenteral nutrition, selective bowel decontamination and suprapubic cathe. Dig Surg. 2019;36(5):394–401.

    PubMed  Google Scholar 

  105. Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: An analysis of the prognostic significance of an initial nondefinitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and perioperative intraperitoneal chemoth. Dis Colon Rectum. 2018;61(3):347–54.

    PubMed  Google Scholar 

  106. Arslan NC, Bisgin T, Altay C, Yavuzsen T, Karaoglu A, Canda AE, et al. Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer? J BUON. 2018;23(7):77–83.

    Google Scholar 

  107. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91(6):747–54.

    CAS  PubMed  Google Scholar 

  108. Varban O, Levine EA, Stewart JH, McCoy TP, Shen P. Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. Cancer. 2009;115(15):3427–36.

    PubMed  Google Scholar 

  109. Robella M, Vaira M, Marsanic P, Mellano A, Cinquegrana A, Sottile A, et al. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients. Minerva Chir. 2013;68(6):551–8.

    CAS  PubMed  Google Scholar 

  110. Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goéré D, et al. Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23(12):3891–8.

    PubMed  Google Scholar 

  111. Simkens GA, van Oudheusden TR, Nieboer D, Steyerberg EW, Rutten HJ, Luyer MD, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23(13):4214–21.

    PubMed  Google Scholar 

  112. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, et al. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol. 2008;15(11):3065–72.

    PubMed  Google Scholar 

  113. Huang C-Q, Yang X-J, Yu Y, Wu H-T, Liu Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese Center. PLoS ONE. 2014;9(9):e108509.

    PubMed  PubMed Central  Google Scholar 

  114. Simkens GA, van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, et al. Treatment-related mortality after cytoreductive surgery and HIPEC in patients with colorectal peritoneal carcinomatosis is underestimated by conventional parameters. Ann Surg Oncol. 2016;23(1):99–105.

    PubMed  Google Scholar 

  115. Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22(8):2656–62.

    PubMed  Google Scholar 

  116. Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quénet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23(7):2315–22.

    PubMed  Google Scholar 

  117. Valle SJ, Alzahrani N, Alzahrani S, Bin TT, Liauw W, Morris DL. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: incidence, management and outcomes. Surg Oncol. 2016;25(3):315–20.

    PubMed  Google Scholar 

  118. Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2017;24(4):890–7.

    PubMed  Google Scholar 

  119. Van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, Van Ramshorst B, Luyer MD, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(8):2621–6.

    PubMed  Google Scholar 

  120. Elias D, Borget I, Farron M, Dromain C, Ducreux M, Goéré D, et al. Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers. Eur J Surg Oncol. 2013;39(11):1214–8.

    CAS  PubMed  Google Scholar 

  121. Kuijpers AMJ, Mehta AM, Aalbers AGJ, van Driel WJ, Boot H, Verwaal VJ. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2014;40(8):937–42.

    CAS  PubMed  Google Scholar 

  122. Dewan NA, Daniels A, Zieman G, Kramer T. The national outcomes management project: a benchmarking collaborative. J Behav Heal Serv Res. 2000;27(4):431–6.

    CAS  Google Scholar 

  123. Ellis J. All inclusive benchmarking . J Nurs Manag. 2006;14:377–83.

    PubMed  Google Scholar 

  124. Salazar G de. Benchmarking y marketing en cirugía. In: Aguiló Lucia SA (ed). Gestión Clínica en Cirugía. Aran Ediciones; 2016. pp. 393–404.

  125. J AL, V. SA. Gestión clínica en cirugía. Ediciones A (ed). 2016.

  126. Escrig-Sos J. Métodos actuales para la monitorización y control de calidad de los procesos clínicos. Rev Senol Patol Mamar. 2014;27(2):94–8.

    Google Scholar 

  127. Pera M. Niveles de calidad exigibles en cuanto a tecnología y procedimientos en la cirugía del cáncer de esófago. Cir Esp. 2003;27(2):94–8.

    Google Scholar 

  128. Ortiz H, Codina A. Proyecto del cáncer de recto de la Asociación Española de Cirujanos (Vikingo): Pasado y futuro. Cirugía Española. 2016;94(2):63–4.

    PubMed  Google Scholar 

  129. Shellenberger TD, Madero-Visbal R, Weber RS. Quality indicators in head and neck operations: a comparison with published benchmarks. Arch Otolaryngol Head Neck Surg. 2011;137(11):1086–93.

    PubMed  Google Scholar 

  130. Bellver Oliver M, Escrig-Sos J, Rotellar Sastre F, Moya-Herráiz Á, Sabater-Ortí L. Outcome quality standards for surgery of colorectal liver metastasis. Langenbeck’s Arch Surg. 2020;405(6):745–56.

    Google Scholar 

  131. Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, Königsrainer I, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7(12):567.

    PubMed Central  Google Scholar 

  132. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–70.

    PubMed  Google Scholar 

  133. Punt CJA, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99:998–1003.

    PubMed  Google Scholar 

  134. Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS open. 2019;3(5):585–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14(8):2270–80.

    PubMed  Google Scholar 

  136. Cheng H, Chen BPH, Soleas IM, Ferko NC, Cameron CG, Hinoul P. Prolonged operative duration increases risk of surgical site infections: a systematic review. Surg Infect. 2017;18:722–35.

    Google Scholar 

  137. Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg. 2014;149(2):170–5.

    PubMed  Google Scholar 

  138. Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res. 2019;234:240–8.

    PubMed  Google Scholar 

  139. Silber JH, Williams SV, Krakauer H, Schwartz JS. Hospital and patient characteristics associatedwith death after surgery: a study of adverse occurrence and failure to rescue. Med Care. 1992;30(7):615–27.

    CAS  PubMed  Google Scholar 

  140. Massarweh NN, Anaya DA, Kougias P, Bakaeen FG, Awad SS, Berger DH. Variation and impact of multiple complications on failure to rescue after inpatient surgery. Ann Surg. 2017;266(1):59–65.

    PubMed  Google Scholar 

  141. Sinukumar S, Mehta S, Damodaran D, Rajan F, Zaveri S, Ray M, et al. Failure-to-rescue following cytoreductive surgery with or without HIPEC is determined by the type of complication—a retrospective study by INDEPSO. Indian J Surg Oncol. 2019;10(Suppl 1):71–9.

    PubMed  PubMed Central  Google Scholar 

  142. Li KY, Mokdad AA, Minter RM, Mansour JC, Choti MA, Augustine MM, et al. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2017;214:209–15.

    PubMed  Google Scholar 

  143. Passot G, Vaudoyer D, Villeneuve L, Wallet F, Beaujard AC, Boschetti G, et al. A perioperative clinical pathway can dramatically reduce failure-to-rescue rates after cytoreductive surgery for peritoneal carcinomatosis. Ann Surg. 2017;265(4):806–13.

    PubMed  Google Scholar 

  144. Liu JB, Schuitevoerder D, Vining CC, Berger Y, Turaga KK, Eng OS. Benchmarking perioperative outcomes of cytoreductive surgery for cancer: implications for quality measurement. Ann Surg Oncol. 2020;27(13):5039–46.

    PubMed  Google Scholar 

  145. Birkmeyer JD, Hamby LS, Birkmeyer CM, Decker MV, Karon NM, Dow RW. Is unplanned return to the operating room a useful quality indicator in general surgery? Arch Surg. 2001;136(4):405–11.

    CAS  PubMed  Google Scholar 

  146. Blaj S, Nedelcut S, Mayr M, Leebmann H, Leucuta D, Glockzin G, et al. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome. Langenbeck’s Arch Surg. 2019;404(5):541–6.

    Google Scholar 

  147. Sabater L, Mora I, Gámez del Castillo JM, Escrig-Sos J, Muñoz-Forner E, Garcés-Albir M, et al. Outcome quality standards in pancreatic oncologic surgery in Spain. Cir Esp. 2018;96(6):342–51.

    PubMed  Google Scholar 

  148. Simkens GA, Razenberg LG, Lemmens VE, Rutten HJ, Creemers GJ, de Hingh IH. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol. 2016;42(6):794–800.

    CAS  PubMed  Google Scholar 

  149. Saxena A, Valle SJ, Liauw W, Morris DL. Allogenic blood transfusion is an independent predictor of poorer peri-operative outcomes and reduced long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of 936 cases. J Gastrointest Surg. 2017 ;21(8):1318–27.

    PubMed  Google Scholar 

  150. Ihemelandu C. Inflammation-based prognostic scores: utility in prognostication and patient selection for cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal metastasis of colonic origin. Ann Surg Oncol. 2017;24(4):884–9.

    PubMed  Google Scholar 

  151. Sugarbaker PH. Peritonectomy procedures. In: PH Sugarbaker, editor. Peritoneal carcinomatosis: a multidisciplinary approach. Springer; 2007. p. 247–64.

    Google Scholar 

  152. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14(1):128–33.

    CAS  PubMed  Google Scholar 

  153. Kuijpers AM, Hauptmann M, Aalbers AG, Nienhuijs SW, De Hingh IH, Wiezer MJ, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol. 2016;42(2):244–50.

    CAS  PubMed  Google Scholar 

  154. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    PubMed  PubMed Central  Google Scholar 

  155. Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery. 2010;147(3):339–51.

    PubMed  Google Scholar 

  156. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27(2):97–132.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Valencian Institute of Oncology, General and Gastrointestinal Surgery, Valencia, Spain

    Alfonso García-Fadrique MD, PhD & Rafael Estevan Estevan MD, PhD

  2. Hospital Clínico Universitario, Department of Surgery, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

    Luis Sabater Ortí MD, PhD

Authors
  1. Alfonso García-Fadrique MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafael Estevan Estevan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis Sabater Ortí MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfonso García-Fadrique MD, PhD.

Ethics declarations

Disclosures

Alfonso García-Fadrique, Rafael Estevan Estevan, and Luis Sabater Ortí declare no conflicts of interest. In loving memory of Prof. Javier Escrig Sos MD PhD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 22 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

García-Fadrique, A., Estevan Estevan, R. & Sabater Ortí, L. Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 29, 188–202 (2022). https://doi.org/10.1245/s10434-021-10642-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10642-6

Search

Navigation